Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Ford

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Science (New York, N.Y.)|March 6, 2014
Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virusChasity D Andrews, William R Spreen, Hiroshi Mohri, et al.
American Journal of Obstetrics & Gynecology MFM|April 1, 2023
The Ohio Maternal Safety Quality Improvement Project: initial results of a statewide perinatal hypertension quality improvement initiative implemented during the COVID-19 pandemicPatrick Schneider, Allison Lorenz, Michelle C Menegay, et al.
Science Translational Medicine|January 16, 2015
A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challengeChasity D Andrews, Yun Lan Yueh, William R Spreen, et al.
British Journal of Clinical Pharmacology|July 9, 2021
Multiparametric magnetic resonance imaging to characterize cabotegravir long-acting formulation depot kinetics in healthy adult volunteersBeat M Jucker, Edward J Fuchs, Sarah Lee, et al.
Lancet (London, England)|December 14, 2020
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority studyEdgar T Overton, Gary Richmond, Giuliano Rizzardini, et al.
The Lancet. HIV|October 2, 2023
Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trialMark A Marzinke, Brett Hanscom, Zhe Wang, et al.
The Journal of Infectious Diseases|March 18, 2022
Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084Susan H Eshleman, Jessica M Fogel, Estelle Piwowar-Manning, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Science (New York, N.Y.)|March 6, 2014
Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virusChasity D Andrews, William R Spreen, Hiroshi Mohri, et al.
American Journal of Obstetrics & Gynecology MFM|April 1, 2023
The Ohio Maternal Safety Quality Improvement Project: initial results of a statewide perinatal hypertension quality improvement initiative implemented during the COVID-19 pandemicPatrick Schneider, Allison Lorenz, Michelle C Menegay, et al.
Science Translational Medicine|January 16, 2015
A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challengeChasity D Andrews, Yun Lan Yueh, William R Spreen, et al.
British Journal of Clinical Pharmacology|July 9, 2021
Multiparametric magnetic resonance imaging to characterize cabotegravir long-acting formulation depot kinetics in healthy adult volunteersBeat M Jucker, Edward J Fuchs, Sarah Lee, et al.
Lancet (London, England)|December 14, 2020
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority studyEdgar T Overton, Gary Richmond, Giuliano Rizzardini, et al.
The Lancet. HIV|October 2, 2023
Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trialMark A Marzinke, Brett Hanscom, Zhe Wang, et al.
The Journal of Infectious Diseases|March 18, 2022
Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084Susan H Eshleman, Jessica M Fogel, Estelle Piwowar-Manning, et al.
Pageof 3